NYMXF (Nymox Pharmaceutical) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nymox Pharmaceutical's Free Cash Flow for the three months ended in Sep. 2024 was $0.00 Mil. Nymox Pharmaceutical's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Nymox Pharmaceutical's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Nymox Pharmaceutical's current FCF Yield % is -31.30%.

The historical rank and industry rank for Nymox Pharmaceutical's FCF Margin % or its related term are showing as below:

NYMXF' s FCF Margin % Range Over the Past 10 Years
Min: -201000 Med: -2621.07 Max: 81200
Current: 81200

During the past 13 years, the highest FCF Margin % of Nymox Pharmaceutical was 81200.00%. The lowest was -201000.00%. And the median was -2621.07%.

NYMXF's FCF Margin % is ranked better than
99.9% of 1016 companies
in the Biotechnology industry
Industry Median: -140.87 vs NYMXF: 81200.00

Nymox Pharmaceutical FCF Margin % Historical Data

The historical data trend for Nymox Pharmaceutical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical FCF Margin % Chart

Nymox Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-6,405.17

-201,000.00

Nymox Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	17,940.00	-

Competitive Comparison of Nymox Pharmaceutical's FCF Margin %

For the Biotechnology subindustry, Nymox Pharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Nymox Pharmaceutical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nymox Pharmaceutical's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-4.06	/	0
	=	%

Nymox Pharmaceutical's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	0	/	0
	=	%

Nymox Pharmaceutical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel